



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Yoshinaga et al.

Serial No.: 09/728,420

Filed: November 28, 2000

For: Novel Polypeptides Involved in Immune Response

Docket No.: A-579C

ATTORNEY'S STATEMENT PURSUANT TO 37 CFR § 1.821

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

I hereby state that the substitute paper copy and substitute computer readable form (CRF) of the "Sequence Listing" submitted herewith for the above-mentioned patent application are the same, and contain no new matter.

Respectfully submitted,

Robert B. Winter
Attorney/Agent for Applicant(s)
Registration No.: 34,458
Phone: (805) 447-2425
Date: MAY 17, 2002

Please send all future correspondence to:

U.S. Patent Operations/RBW
Dept. 4300, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799

EXPRESS MAIL CERTIFICATE

"Express Mail" mail labeling number:

EL360694002US

Date of
Deposit:

May 17, 2002

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, DC 20231.

Lynne Buchsbaum
Printed Name

Lynne Buchsbaum
Signature